Biological Bank for Atrial Fibrillation and Stroke

Study Overview
=================
Brief Summary
-----------------
Atrial fibrillation (AF) is the most common cardiac arrhythmia encountered in clinical practice. This arrhythmia is responsible for 15% of strokes and more than 30% of strokes on people over 65 years. According to studies, 30 to 40% of isolated atrial fibrillations could be familial. Atrial fibrillation has significant genetic heterogeneity. About 40 genes have been identified as potentially involved. Studies have identified genes common to the risk of atrial fibrillation and stroke. Despite the pathophysiology of atrial fibrillation has been intensively and extensively studied for almost a century, there are still many questions. The pathophysiology is not sufficiently understood to allow finding more effective therapies. It is necessary to identify genetic determinants and thus potentially new pharmacological targets more adapted. The establishment of a biological database will test hypotheses concerning the genetic origin and thromboembolic process of atrial fibrillation and associated stroke.

Official Title
-----------------
Biological Bank for Studies Related to Atrial Fibrillation and Stroke

Conditions
-----------------
Stroke, Atrial Fibrillation

Intervention / Treatment
-----------------
* Biological: Blood taken
* Genetic: Blood taken
* Genetic: Blood taken


Participation Criteria
=================
Eligibility Criteria
-----------------
Group 1a: Inclusion Criteria : Atrial Fibrillation history Exclusion Criteria : No Atrial Fibrillation history patient who didn't signed consent Group 1b Inclusion Criteria : Atrial Fibrillation history Scheduled electrophysiological exploration or Atrial Fibrillation ablation Exclusion Criteria : No Atrial Fibrillation history pregnant women patient who didn't signed consent Group 1c Inclusion Criteria : Atrial Fibrillation history Stroke history Exclusion Criteria : patient who didn't signed consent Group 2 Inclusion Criteria : patient over 80 Electrocardiography : sinusal rhythm Transthoracic echocardiogram : no left atrial dilatation Exclusion Criteria : atrial fibrillation history Transthoracic echocardiogram : Left atria >25cm², > 34m/m2), LVEF (left ventricular ejection fraction) < 50% Electrocardiography : QRS > 90 ms cardiac pathologies (excepted hypertension and valvulopathies) History of stroke and transient ischemic attack patient who didn't signed consent Group 3 Inclusion Criteria : cryptogenic stroke history before 50 yo No Atrial Fibrillation history Exclusion Criteria : Atrial Fibrillation history stroke over 50 yo patient who didn't signed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group 1a<br>Patient with atrial fibrillation and without stroke history. | Biological: Blood taken<br>* Collection of clinical data<br>Genetic: Blood taken<br>* Collection of DNA<br>|
| Group 1b<br>Patient with atrial fibrillation with scheduled electrophysiology exploration or ablation. | Biological: Blood taken<br>* Collection of clinical data<br>Genetic: Blood taken<br>* Collection of DNA<br>Genetic: Blood taken<br>* Collection of plasma<br>|
| Group 1c<br>Patient with atrial fibrillation and with stroke history. | Biological: Blood taken<br>* Collection of clinical data<br>Genetic: Blood taken<br>* Collection of DNA<br>|
| Group 2<br>Patients aged over 80 years old and without history of atrial fibrillation. | Biological: Blood taken<br>* Collection of clinical data<br>Genetic: Blood taken<br>* Collection of DNA<br>|
| Group 3<br>Patient with cryptogenic stroke history before the age of 50. | Biological: Blood taken<br>* Collection of clinical data<br>Genetic: Blood taken<br>* Collection of DNA<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quality of DNA sample | Quality is based on the measure of the purity of DNA with absorbance assay at 260/280nm on a spectrophotometer. For Plasma sample, purity is based on absence of hemolyzed blood by visual observation. | 1 day (the day of the storage) | 
| Quality of Plasma sample | Quality is based on the purity of Plasma sample that is based on absence of hemolyzed blood by visual observation. | 1 day (the day of the storage) | 
| Quality of preservation of the sample | The quality of preservation of the sample throughout the conservation duration is based on the number of freezing/thawing of each cryotube that will be notified. As weel as any interruption in the freezing process (power failure, freezer failure). | 7 years (during all the duration of the collection) |